Drug Development

Foresee Pharmaceuticals signals a major shift to commercialization, appointing Brian J. Groch to lead the launch of its 6-month CPP treatment, FP-001.

Millions suffer through frequent eye injections for wet AMD. A new partnership aims to change that with a targeted drug and microneedle system, promising a precision strike at the disease's core.

Ultragenyx bets 62% of its budget on R&D while unprofitable. Its new Impact Report reveals a strategy where patient access and ESG are the real assets.

A new deal between genomics giant Illumina and startup Bifrost Biosystems isn't just a business transaction. It’s a strategic play to rewire the very process of drug discovery.

Supplement giant Niagen Bioscience is betting big on a new drug for a rare disease. Can its NAD+ science make the leap from wellness to a real cure?

With a PDUFA date set, Arcutis' ZORYVE could soon offer a once-daily, non-steroidal cream for infants, addressing a massive unmet need for families.

With bladder cancer recurrence rates stubbornly high, UroGen Pharma is advancing a novel oncolytic virus into human trials. Can it finally break the cycle?

With record Q1 sales and key milestones for iDose® TR and Epioxa, all eyes are on Glaukos's July 29 financial release for its next growth chapter.

Preclinical data shows GLIX1 can make PARP inhibitors effective in previously unresponsive tumors, a potential game-changer for 50% of ovarian cancer patients.

Evogene and Tel Aviv University are pairing generative AI with lab validation to bridge the 'valley of death' for academic drug research in Israel.

Keenova Therapeutics' positive Phase 3 results for XIAFLEX could bring the first-ever approved drug for plantar fibromatosis, a painful, disabling condition.

For families battling Duchenne, treatment is a daily trade-off. Now, a new drug class promises to ease this burden, signaling a new era for rare disease care.

Avacta taps veteran dealmaker Dr. Patrick Vink as it nears a pivotal data reveal for its pre|CISION® platform, signaling a shift from R&D to high-stakes commercial strategy.

After a clinical hold on its lead drug, Quantum BioPharma is spending heavily on marketing. Is it a bold play for survival or a sign of desperation?

A new deal to develop cancer drugs reveals a seismic shift: China is no longer just a market, but a core engine in a new global innovation network.

Seattle-based A-Alpha Bio just launched Atlas, a platform that doesn't just design drugs with AI, but generates the massive datasets needed to make AI work.

AstraZeneca's new deal with genomics firm Helix isn't just a partnership; it's a bet on a future where drug discovery is driven by massive data vaults.

A new partnership brings autonomous AI agents to the lab, promising to slash drug development timelines. But can these 'AI scientists' be trusted with our future medicines?

Nanoscope's revolutionary MCO-010 gene therapy offers hope to millions with retinal disease. A new partnership with Catalent is the critical final step.

Cytokinetics is set to unveil groundbreaking data for aficamten, a therapy that could become the first-ever approved treatment for non-obstructive HCM.